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H I G H L I G H T S
• Endometrium of complete moles contains a high density of endometrium infiltrating T cells.
• NK-T cell density in endometrium of complete moles is linked to its spontaneous regression.
• The immune cell landscape in the endometrium of complete moles differs between patients with spontaneous regression and patients with progression to post-
molar GTN.
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Objective. In 15% of patients with complete hydatidiformmole (CHM), disease progresses to post-molar ges-
tational trophoblastic neoplasia (GTN) after curettage. Tumor infiltrating lymphocytes (TILs) are essential in
overcoming disease inmany tumors. Infiltrating lymphocyte composition and densitymay influence trophoblast
regression and development of post-molar GTN. We analyzed immune cell composition and density in
curettaged endometrium of patients with CHM which spontaneously regressed, and of patients with CHM
which progressed to post-molar GTN.
Methods. Sixteen patients with CHM and spontaneous regression, and 16 patients with CHM which
progressed to post-molar GTN were selected. Immune cell composition and density of natural killer (NK) cells,
natural killer T (NKT)-like cells, Cytotoxic T cells, T-Regulatory and T-Helper cells, were determined bymultiplex
immunohistochemistry (mIHC).
Results. Curettaged endometrium of patients with CHM and spontaneous regression contained a slightly
higher number of immune cells compared to patients with CHM which progressed to post-molar GTN. NKT-
like cell density was significantly higher in patients with spontaneous regression compared to patients with
CHM which progressed to post-molar GTN (483 ± 296 vs.295 ± 143 (mean ± SD), p = 0.03) respectively.
NKT-like cell density in the spontaneous regression group was split in ‘high’ and ‘low’ (i.e. above and below
the median number of NKT-like cells). In patients with high NKT-like cell density, hCG normalized earlier than
in patients with lowNKT-like cell density (9.5weeks, (range 3.7–14) vs. 12.9weeks, (range 8.6–17.9), p=0.05).
Conclusion. A high number of NKT-like cells in the endometrium of CHMsmay contribute to spontaneous re-
gression of molar trophoblast cells.






Natural killer t-like cells
1. Introduction
Gestational trophoblastic disease represents a heterogeneous group
of pregnancy related disorders originating from placental tissue [1]. The
most common form of gestational trophoblastic disease is the
hydatidiformmole, which is subdivided in complete (CHM) and partial
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hydatidiformmoles [1,2]. CHMs are diploid and androgenetic, resulting
from duplication of the haploid genome of a single sperm, or dispermic
fertilization of an ovum. In both cases, maternal DNA is lost, and nuclear
DNA is entirely paternal [1]. In approximately 15% of all CHMs, tropho-
blastic activity after uterine suction curettage persists, a condition re-
ferred to as post-molar gestational trophoblastic neoplasia (GTN) [3].
Although much effort has been put into understanding the develop-
ment from hydatidiform moles to GTN, the underlying mechanism is
still unclear [4–6].
Immune tolerance towards the trophoblast cells still present
after suction curettage could be a contributing factor to the develop-
ment of post-molar GTN, since studies show that in normal pregnan-
cies immune tolerance is essential [7–9]. In normal pregnancies,
trophoblast cells expressing both maternal and paternal antigens
are tolerated by the surrounding maternal immune system to sus-
tain foetal development [7,8,10]. Trophoblast cells do not express
the classical major histocompatibility (MHC) class I molecules
human leukocyte antigen (HLA) -A, and\\B, or MHC class II mole-
cules, which are involved in T cell mediated recognition [9–11].
The immune checkpoint programmed death ligand 1 (PD-L1), is
highly expressed on the syncitiotrophoblast and functions as an
immune suppressant when bound to its receptor programmed
death 1 (PD-1) [12]. In mice, a blockade or deficiency of PD-L1 re-
sulted in decreased foetal survival rates [8]. Trophoblast cells of
both hydatidiformmoles and GTNs highly express PD-L1, suggesting
that the PD-1/PD-L1 pathway might be involved in uncontrollable
growth of these cells, leading to malignant tissue formation
[13–17]. A recent study showed that anti PD-1 therapy in patients
with chemo-resistant GTNwas successful in three out of four treated
patients [16].
In many tumor types, a high number of tumor infiltrating lympho-
cytes (TILs) is beneficial for clinical outcome of cancer patients. Absence
or low density of TILs often results in a poor response to treatment with
immune checkpoint inhibitors [16,18–21]. Trophoblast cells of CHMs
display many features of malignant cells and have the potential to be-
come malignant. Therefore, an inadequate immune response towards
trophoblast cells from CHMs, may contribute to progression into post-
molar GTN. Since knowledge of immune cell presence in CHMs is lim-
ited, the aim of this studywas to get insight in immune cell composition
and density in the curettaged endometrial tissue of patients with a CHM
which spontaneously regressed after suction curettage and of patients
with a CHMwhich progressed to post-molar GTN.
2. Methods
2.1. Patients
We selected 16 patients with complete hydatidiform moles which
spontaneously regressed after suction curettage and 16 patients with
complete moles which progressed to post-molar GTN. Selection was
based on the availability of formalin-fixed andparaffin-embedded spec-
imens (FFPEs) of the first curettage at the Radboud university medical
center pathology archive. Sixteen samples of patients with a CHM and
progression to post-molar GTN were available for further analysis. To
achieve an equal amount of cases and controls, 16 samples of patients
with a CHM followed by spontaneous regression were included.
Follow-up data was retrieved from the Dutch Central Registry for
Hydatidiform Moles (DCRHM). Patient data are collected in this volun-
tary registry since 1977. For patients with spontaneous regression, the
minimum follow-up period after normalizationwas sixmonths. For pa-
tients diagnosed with post-molar GTN, follow-up was one year after
normalization of hCG levels. No patients of the spontaneous regression
or post-molar GTN group showed signs of intra-uterine retention of tro-
phoblast tissue. Patients with a history of auto-immune diseases, recur-
rent hydatidiform moles or with no treatment data available were
excluded. Post-molar GTN was defined according to the FIGO 2000
guideline (i.e., mola hydatidosa with serum hCG plateauing for three
consecutive weeks or rising over a period of two consecutive weeks)
[22]. In line with the Dutch guidelines, the following criterion was
added to this definition: at least one of the values should exceed the
95th percentile of an hCG normogramof uneventful hCG as constructed
by Yedema et al. [23]. The local ethical committee of the Radboud Uni-
versity Medical Center approved this study (reference number
2018–4132).
2.2. Multiplex immunohistochemistry
Of each selected patient, hematoxylin-eosin (HE) slides of all available
FFPE specimens, varying from 2 to 8 tissue blocks, were assessed for the
presence of both endometrial and implantation trophoblast tissue by an
experienced gyneco-pathologist. The selected FFPE specimens of the 32
selected patients were cut in sequential sections of 4-μm thickness and
mounted on glass slides. Control slides included tonsil, colon, liver and
pancreatic tissue [24]. One slide was subjected to hematoxylin-eosin
(HE) staining, and specific endometrial and trophoblast regions were
indicated by an experienced gyneco-pathologist. Another slide was
subjected to seven-color multiplex immunohistochemistry (mIHC)
in sequential staining cycles using Opal 7-color Automation IHC Kit
(NEL801001KT; PerkinElmer) on the BOND RX IHC & ISH Research Plat-
form (Leica Biosystems). A multiplex panel for the detection of different
lymphocyte populations was optimized as described before [25] and ap-
plied on tissue sections, consisting of anti-CD45RO 1:1000 (MS-112,
clone UCHL-1; Thermo Scientific) with Opal 620, anti-CD8 1:200
(M7103, clone C8/144B; Dako) with Opal 690, anti-CD3 1:200 (RM-
9107, clone Sp7; Thermo Fisher) with Opal 520, anti-Foxp3 1:100
(14–4777, clone 236A/E7; eBioscience Affymetrix) with Opal 540 anti-
CD56 1:500 (156R-94, clone MRQ-42; Cell Marque) with Opal 570, and
anti-pan Cytokeratin 1:1500 (ab86734, clone AE1/AE3 + 5D3; Abcam)
with Opal 650. Primary antibody incubations were performed for 1 h,
secondary antibody Opal Polymer HRP Ms. + Rb incubations for
30 min, and Opal reagent incubations for 10 min, all at room tempera-
ture. All epitope retrievals and antibody-TSA complex removals were
performed using Bond Epitope Retrieval 2 (AR9640, Leica Biosystems).
Tissue sections were counterstained with DAPI and mounted in
Fluoromount-G (0100–01, SouthernBiotech, Birmingham, AL, USA).
The slides were scanned using the Vectra Automated Quantitative
Pathology Imaging System (Version 3.0.4, PerkinElmer). In each sample,
the endometrial tissue was selected using Phenochart (Version 1.0.9,
PerkinElmer Inc.), for multispectral imaging at 20× magnification,
based on HE slides annotated by the gyneco-pathologist. Only endome-
trial regions were analyzed, since no immune cell infiltration was de-
tected in trophoblast. Spectral unmixing of Opal fluorophores, DAPI,
autofluorescence, and downstream image analysis was performed
with inForm software (Version 2.2.1, PerkinElmer). The pathologist
and researchers were blinded to patient follow-up details during the
staining, scanning and analysis period.
A selection of 30–35 representative original multispectral images
were used to train the inForm software to distinguish hemorrhagic en-
dometrial tissue from non-hemorrhagic endometrial tissue, trophoblast
tissue, and background, based on DAPI and autofluorescence. Settings
for adaptive cell segmentation were based on DAPI and membrane sig-
nals. All the settings applied to the training images were saved in an al-
gorithm to allow batch analysis of multiple original multispectral
images of the same CHM slides.
2.3. Image cytometry
Segmented cell data was converted into Flow Cytometry Standard
(FCS) files, and analyzed using FlowJo software (v10; Tree Star). Pheno-
type of the immune cells in non-hemorrhagic endometrial tissue re-
gions were determined by gating cells and divided by surface area of
the tissue region (mm2).
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2.4. Statistical analysis
As datawere not normally distributed,we used theMann-WhitneyU
test to compare baseline characteristics between the spontaneous
regression and post-molar GTN group. Immune cell density of the im-
mune phenotypes was calculated per mm2 non-hemorrhagic endome-
trial tissue, and means were compared with the two-sided Students
t-test when data was normally distributed after log-transformation.
When after log-transformation data was skewed we used the Mann-
Whitney U test. A p-value of ≤0.05 was considered significant. In this
hypothesis-generating study, we did not correct for multiple testing.
3. Results
Baseline characteristics of the included patients are displayed in
Table 1. There was no difference between both groups in terms of pa-
tients' age, and gestational age at diagnosis. Pre-evacuation serum hCG
levels tended to behigher in the post-molarGTNgroup, althoughnot sig-
nificant (p = 0.06). Samples of the post-molar GTN group contained
more hemorrhagic tissue within the imaged tissue areas compared to
samples of the spontaneous regression group (Table 1). We selected en-
dometrial tissue regions formultispectral imaging at a 20×magnification
(Fig. 1A and\\B). Different immune cell populations were detected
within samples (Fig. 1C). Non-hemorrhagic tissue could adequately be
separated from hemorrhagic tissue and background by tissue segmenta-
tion with inForm (Fig. 1D). Only non-hemorrhagic endometrial tissue
was included in the analysis. Single cell information was transformed
into FCS files and further analyzed using image cytometry (Fig. 2). We
calculated immune cell density per mm2 non-hemorrhagic endometrial
tissue in both groups for natural killer (NK) cells (CD56+), natural killer
T (NKT)-like cells (CD56+, CD3+), total T cells (Cytotoxic T cells+ T regs
+NKT-like cells+Thelper cells), cytotoxic T cells (CD8+), T-helper cells
(CD8−, FOXP3−, CD3+), and T-regulatory cells (FOXP3+), (Fig. 3). T cell
populationswere not further divided into CD45ROpositive and negative,
since no reliably discrimination between these populationswas possible.
Therefore, the CD45RO marker was excluded from the analysis.
In general, the curettaged non-hemorrhagic endometrial tissue of
patients with a CHM and spontaneous regression contained a slightly
higher number of total CD3+ immune cells compared to the curettaged
non-hemorrhagic endometrial tissue of patients with CHM which
progressed to post-molar GTN (Fig. 3). Median density of cytotoxic T
cells, T helper cells, and T regulatory cells were similar in both groups
(Fig. 3). Although not significant, the number of NK cells observed in
the spontaneous regression group, tended to be higher than the number
of NK cells in the post-molar GTN group. Non-hemorrhagic curettaged
endometrial tissue of patients with CHM and spontaneous regression
after curettage had a significantly higher number of NKT-like cells per
mm2 compared to endometrial tissue of patients which progressed to
post-molar GTN (483 ± 296 versus 295 ± 143 (mean ± SD) NKT-like
cells per mm2, respectively, p = 0.03), (Fig. 3).
To investigate the relevance of a higher number of NKT-like cells in
the curettaged endometrial tissue of CHM patients for clinical outcome,
each of the two patient populations (i.e. patients with a CHM which
spontaneously regressed after suction curettage, and patients with a
CHM which progressed to post-molar GTN), were divided in NKT-like
cell density above and below themedian density. There was no correla-
tion between pre-evacuation hCG level and NKT-like counts. (Pearson
correlation−0.57, p=0.11). In patientswith CHMand spontaneous re-
gression after curettage, who had anNKT-like cell infiltrate in the endo-
metrial tissue above the median, mean time until hCG normalization
took 9.5 weeks (±3.0) compared to 12.9 weeks (±3.3) in patients
with an NKT-like cell density below the median (p = 0.05), (Fig. 4). In
patients with a CHM which progressed to post-molar GTN, and there-
fore treated with methotrexate (MTX) chemotherapy, mean number
of MTX courses needed until hCG normalization was 6.3 (±3.9) in pa-
tients with an NKT-like cell density above the median, and 7.4 (±4.6)
in patients with an NKT-like cell density below the median, (p= 0.77).
4. Discussion
4.1. Main findings
Significantly more CD3+CD56+ NKT-like cells were present in the
endometriumof patientswith a CHMand spontaneous regression, com-
pared to patients with a CHM which progressed to post-molar GTN
(Mean ± SD 483 ± 296 versus 295 ± 143 cells per mm2, respectively,
p = 0.03). Also, patients in the spontaneous regression group tended
to normalize earlier when NKT-like cell infiltrate in the endometrium
was above the group median (mean 9.5 weeks, ±3.0) compared to pa-
tients with a NKT-like cell infiltrate below the group median (mean
12.9 weeks, ±3.3), p = 0.05. These observations may indicate that
NKT-like cells influence spontaneous regression of CHMs after
curettage.
4.2. Strengths and limitations
This study is the first to use seven-color mICH to simultaneously
quantify different immune cells within the curettaged endometrial tis-
sue of patients with a CHM. With this technique, we were able to ana-
lyze presence and density of five immune cell phenotypes within one
sample, and link trophoblast regression to density of NKT-like cells. An-
other advantage of this technique is that it offers detailed information
regarding distribution of immune cell phenotypes, while maintaining
the morphological context of the tissue. Although selection of the ana-
lyzed samples was based on presence of endometrial and implantation
trophoblastic tissue, retrieval of these samples was through uterine cu-
rettage. Therefore, we were unable to apprehend the exact approximity
of the endometrial tissue to the trophoblast cells. Although a large part
of the analyzed endometrial tissue will be representative of the decidua
basalis and capsularis located at the implantation site, a part of themea-
sured immune cell populations might be representative of the decidua
parietalis. This however is true for all samples used in this study and
may have had an equal influence on both the spontaneous regression,
and the post-molar GTN group. Additionally, uterine suction curettage
Table 1
Baseline characteristics of patients with CHM and a spontaneous regression after curettage and patients with post-molar GTNa.
Spontaneous regression Post-molar GTN p-value
N Median (min – max) N Median (min – max)
Age at time diagnosis (years) 16 31 (20–54) 16 31 (20–52) 0.86b
Gestational age (weeks) 10 11 (7–18) 13 11 (9–24) 0.79b
Pre-evacuation hCG level (ng/mL) 6 2,700 (610–5300) 8 5,649 (2550–16,000) 0.06b
Analyzed non-hemorrhagic tissue (mm2) 16 26 (2–138) 16 19 (1–37) 0.31b
Hemorrhagic tissue (mm2) 16 2 (0–4) 16 3 (0–7) 0.01b,c
a Data shown for all patients with baseline features available.
b Mann-Whitney U test.
c Significant at p < 0.05 level.
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is the least invasivemanner to remove amolar pregnancy, and all retro-
spective and future samples most probably will be collected in this
manner.
Because post-molar GTN is rare, we were limited by a retrospective
design and a relatively small sample size. Differences in absolute NK
cell numbers may exist between the spontaneous regression and post-
molar GTNgroup, but our studymayhave been underpowered to detect
this difference. This also may apply for the role of NKT-like cells in the
clearance of CHMs in combinationwith chemotherapy. Unlikemostma-
lignant diseases, diagnosis of post-molar GTN is currently based on clin-
ical parameters, i.e. level and course of serum hCG, instead of
confirmation by histology [1,22]. To ensure diagnosis of post-molar
GTN is not erroneously based on a missed uterine retention, macro-
scopic complete removal of themolar pregnancy was confirmed during
or after the initial uterine curettage.
4.3. Interpretation
Themost prevalent cell typewithin the endometrial tissue of CHMpa-
tientswere the CD56+NK cells. This cell type is also themost abundant in
the decidua of normal pregnancies, representing 70% of the leukocytes
present in utero26. Of the two subpopulations of NK cells present in nor-
mal pregnancies: CD56dim CD16+, and CD56bright CD16−, the majority
of decidual NK cells (dNK cells) consists of the less cytotoxic CD56bright
Fig. 1.Multiplex immunohistochemistry of curettagedendometrial tissue of a patientwith a CHM. Slideswere stainedwith a lymphocyte panel containingCD3, FOXP3, CD8, CD56, CD45ro,
pan-cytokeratin (CK) and DAPI, and scanned with the Vectra 3. A and B) Regions of endometrial tissue were selected for multispectral images (MSIs) at 20× magnification (light-blue
rectangles) from the prescans (using DAPI, FITC and Cy5 filters) within Phenochart. From these overviews DAPI (blue), CD3 (green), CK (red) and autofluorescence coming from
hemorrhagic tissue areas (green) are mainly visible. Scale bars are 3 and 1 mm, respectively. C) Composite image from unmixed MSIs using inForm Cell Analysis software, visualizing
CD3 (red), CD8 (cyan), FOXP3 (green), CD45ro (orange), CD56 (yellow), pan-CK (white) and DAPI (blue) at 20× magnification. Scale bar is 0.1 mm. D) Overview of batch-analyzed
tissue segmentation dividing the tissue into “non-hemorrhagic endometrial tissue” (grey) and “hemorrhagic endometrial tissue” (black) regions. Only the areas of non-hemorrhagic
endometrial tissue were analyzed. Scale bar is 1 mm.
Fig. 2. Image cytometry gating strategy. Cells were segmented using in Form Cell Analysis software based on DAPI and FOXP3 as nuclear signals, and splitted using membrane signals.
Single cell information was transformed into an.fcs file and further analyzed using image cytometry within Flow Jo. In the left panel, single cell events within the intact tissue are
visualized in its spatial context. In the middle panel, CD8 positive and FOXP3 positive cells are gated out from the sample. In the right panel, cells negative for CD8 and FOXP3 are
further gated for CD56 positivity and/or CD3 positivity. From here different phenotypes were extracted: NK cells (CD56+), NKT-like cells (CD56+,CD3+), Cytotoxic T cells (CD8+), T-
regulatory cells (FOXP3+), T-helper cells (CD56−, CD8−, FOXP3−, CD3+), and total T cells (Cytotoxic T cells + T regs + NKT-like cells + T helper cells). This figure represents the
gating of one of the samples used in this study.
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CD16− phenotype [10]. The origin of these dNK cells is still unclear. Pos-
sibly, NK cells are recruited from other organs or from peripheral blood
to the decidua, where they undergo tissue-specific differentiation. An-
other theory is that dNK cells originate from hematopoietic progenitor
cells or endometrial NK cells residing in the endometrium, which
proliferate and differentiate into dNK cells during early pregnancy [27].
Regardless, dNK cells are thought to play an important role in pregnan-
cies, promoting uterine vascular change, necessary for maternal blood
flow through the placenta [26]. In the pre-malignant CHM, the role of
dNK cells might be different. Biologically, NK cells respond to tumor
Fig. 3. Number of immune cells present per mm2 in endometrial tissue of patients with CHM and a spontaneous regression after curettage (spontaneous) and patients with post-molar
GTN (persistent). Lines display median with IQ-range. ⁎Significant at the p ≤ 0.05 level.






























Time to normalization in patients with a CHM and spontaneous regression
Fig. 4. Time until normalization in patients with a CHMand spontaneous regression after suction curettage. Thin line represents patients with number of NKT cells above themedian, thick
line represents patients with number of NKT cells below the median.
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formation by killing MHC class I negative cells. Indeed, trophoblast cells
lack the classical MHC class I molecules HLA-A and\\B, they however
do expressHLA\\C,HLA-E andHLA-G.HLA-C is themost dominant ligand
for killer-cell immunoglobulin-like receptors (KIR), expressed byNK cells.
Interaction between these receptors and ligands results in inhibition of
cytotoxic functions of NK cells [9,11,28]. NK cell function is furthermore
inhibited following interactions with HLA-E and HLA-G [26,29]. Although
these interactions might result in NK cell tolerance towards proliferating
trophoblast cells, conversely, reduced HLA-G expression was recently
linked to monochemotherapy resistance of gestational choriocarcinomas
[30]. Therefore, the exact role of NK cells in endometrial tissue of CHMpa-
tients remains to be elucidated.
CD3+CD56+ NKT-like cells were the secondmost prevalent cell type
within the endometrial tissue of CHM patients. They represent a hetero-
geneous group of T cells, consisting of a number of diverse T cell subsets,
including classical NKT cells [31–33]. In normal pregnancies, ~0.5% of the
decidual CD3+ T cell population are classical NKT, a frequency 10 times
higher than observed in peripheral blood [31]. Classical NKT cells are
characterized by the expression of both T and NK cell markers. They dif-
fer from conventional T cells in the recognition of antigens [34]. Antigen
recognition in NKT cells occurs via lipids presented by CD1d, a non-
classical MHC class-I-like molecule, whereas T cells detect antigens pre-
sented by conventionalMHCmolecules [35]. As CD1d is expressed by vil-
lous and extravillous trophoblast cells, NKT cells might play a role in
trophoblast regression [31,36]. In mice, activated NKT cells have a dra-
matic impact on pregnancy, resulting in early or mid-gestation preg-
nancy loss and pre-term birth [37]. Additionally, NKT cells may be able
to modulate uterine NK cell function through transactivation [34]. A
study in pregnant mice showed, when NKT cells were activated through
administration of αGalCer, that dNK cells became activated and pro-
duced IFN-gamma within hours of NKT cell activation. Whether this
mechanism is crucial in mediating NKT-cell induced pregnancy loss is
unknown. However, it demonstrates that NKT-cell function is capable
of modulating dNK cell function, and that NKT cells are important in co-
ordinating functional interactions among decidual leukocytes at the
maternal-fetal interface [33,34]. Although due to the design of this
study we mainly identified NKT-like cells, from which only a fraction
are classical CD1d restricted NKT cells, theoretically, a higher number
of NKT-like cells means a higher number of classical NKT cells. However,
there are two types of NKT cells which have distinct and opposing roles.
Type I NKT cells mainly promote immune reactions against tumor cells
and produce cytokines to activate NK and cytotoxic T cells, whereas
type II NKT cells are known to inhibit tumor directed immune reactions
[33,34]. The immune function of NKT cells, either pro-inflammatory or
tolerogenic, depends on tissue type and presence ofmany other immune
cells [33,35,38,39]. Thus, NKT cells present in endometrium of CHMs
might be activated or suppressed due to factors derived from trophoblas-
tic cells and surrounding endometrium. Nevertheless, in our study, in-
creased density of NKT-like cells was associated with a greater
occurrence of spontaneous regression. We might therefore suggest that
a predominant fraction of the NKT-like cells excerted the classical im-
mune stimulating NKT cell function. To further elucidate the underlying
biology of NKT cells present in the decidua of patients with trophoblastic
disease, future studies should focus on the identification of classical and
non-classical NKT cells through the use of αGalcer loaded CD1d
multimers. Density of the present classical and non-classical NKT cells
may be compared between different types of trophoblastic disease and
their relation to pre-evacuation hCG levels, time to normalization, and
courses of chemotherapy needed.
Similar to the cellular composition of the decidua during normal
pregnancies, approximately 20% of leukocytes present in the curettaged
endometrium in this study are CD3+ T cells, and of these CD3+ cells,
~70% are CD8+ cytotoxic T cells, and ~30% are CD4+ T helper cells
[26]. We observed no significant differences in density of these immune
cells between the CHM groups. In normal pregnancies, about 5% of the
CD4+ are FOXP3+ regulatory T cells [26]. We observed very low
numbers of FOXP3+ T regulatory cells within the endometrial tissue of
patients in both CHM groups. As chromosomes of CHMs are entirely of
paternal origin, a strong maternal immune response against these tro-
phoblast cells would be expected [1]. Nevertheless, trophoblast cells of
CHMs are able to proliferate and invade maternal tissue, suggesting a
strong local immune tolerance towards these cells. Immune tolerance
induced by FOXP3+ T regulatory cells could be a mechanism. However,
in linewith our results, other studies showed lownumbers of FOXP3+ T
regulatory cells in the endometrium of CHMs, or observed FOXP3+ T
regulatory cells only in associationwith extremely high numbers of T ef-
fector cells [20,40]. Additionally, at the implantation site of normal preg-
nancies, FOXP3+ T regulatory cells are nearly absent [40]. Therefore,
FOXP3+ T regulatory cells may have no primary role in local protection
of trophoblast cells in normal- and molar pregnancies.
5. Conclusion
The expression of immune checkpoint molecules, lack of classical
MHC class I and MHC class II complexes, and low density of immune
stimulating tumor infiltrating lymphocytes may all contribute to a
tolerogenic environment within molar pregnancies and GTN. Con-
versely, presence of a high number of NKT-like cells may preventmalig-
nant cell formation and contribute to tumor regression. This hypothesis
should be tested in additional researchwith the ultimate aim to identify
patients at risk of progression to post-molar GTN at an early stage. The
immune microenvironment is an extensive web where the balance be-
tween immune stimulating and suppressive factors will probably de-
cide whether a CHM wil regress or progress to post-molar GTN.
Althoughwe observeddifferences in immune cell composition and den-
sity between the spontaneous regression and post-molar GTN groups,
prediction of persistance based on the number of the analyzed immune
cells present solely, is currently not possible.
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